EN DE
Watch Align Technology Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Align Technology Inc (ALGN) fair value: what the stock is really worth

As of Nov 4, 2026: fair value (intrinsic value) of Align Technology Inc stock $181, price $165, upside +10.0%, quality 73 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AT Align Technology Inc logo Some data Nov 5, 2026

Align Technology Inc

ALGN · US
Fairly valued, in an uptrend

The stock costs about what our calculation considers fair.

Quality 73/100
Low debt
Generates free cash flow
Ranks above peers (10/14)
Positive coverage
Fair value $181.39 · Fairly valued (+10.0%)
Mixed Growth (revenue 5y +10.3 %/yr in USD)
Thin margins · 10.0% net margin (TTM)
Moderate moat 59/100
Some data
Quality growth

Risks from the AI analysis

🚩Price drop: Demand signals pointing to consumer caution🚩Cheaper rivals erode pricing power🚩Antitrust probes threaten closed ecosystem

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$729.92 $124.88 Fair Value $181.39 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range $124.88 – $729.92 · fair‑value band $119.25 – $235.81 · the $164.90 price screens below the $181.39 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.

Follow Align Technology in your weekly email

Every Wednesday you see whether Align Technology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally.

Show moreShow less

The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth.

This segment also provides Invisalign express, Invisalign lite, and Invisalign moderate; Invisalign Go, Invisalign Go express, and Invisalign Go Plus; retention products, Invisalign training, adjusting tools used by dental professionals during treatment, ancillary Invisalign accessory products, and other oral health products; Invisalign Professional Whitening system; Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions.

Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; exocad, a computer-aided design and computer-aided manufacturing software; orthodontist software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers; and restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons.

This segment also offers Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface for dental consultations; iTero TimeLapse technology for doctors or practitioners to compare a patient's historic 3D scans to the present-day scan; and subscription software, disposables, rents scanners, and pay per scan services.

Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Stock analysis

Align Technology Inc (ALGN) currently trades at $164.90, while our model-based Fair Value estimate is $181.39, so the stock looks roughly fairly valued today (gap 9.1%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $170.09 per share, and 11 of the 24 models we run sit above the $164.90 price.

Bear case: the Economic Profit group reads lowest at $51.89, and 13 of the 24 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $119.25 (bear) to $235.81 (bull), the price of $164.90 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Align Technology Inc reported revenue of $4.0B in FY2025 versus $4.0B in FY2021, a compound +0.5%/yr. Reported net income was $410M in FY2025, compounding −14.6%/yr from FY2021.

Key figures

Market cap $11.8B Large · P/E ratio 24.0 · P/S ratio 2.85 · EPS (TTM) $6.86 · Net margin 10.0% · Return on equity 10.2% · Return on assets (EBIT) 11.5% · Operating margin 18.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (medium confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 17% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −46% fair-value upside, at 10%, ALGN screens cheaper than that median.

Fair Value models

Bear $119.25 Fair Value $181.39 Bull $235.81
Price $164.90 · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($5.83 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $100.30 $156.82 $292.74 77
Growth DCF $96.95 $166.53 $272.13 76
Owner Earnings $53.74 $90.53 $155.68 74
All 24 models by family
DCF Models
FCF DCF $100.30 $156.82 $292.74 77
Owner Earnings $53.74 $90.53 $155.68 74
5Y Revenue Exit $96.89 $170.09 $279.59 71
5Y EBITDA Exit $122.98 $228.67 $376.84 73
5Y P/E Exit $103.62 $186.96 $289.89 69
10Y Revenue Exit $94.38 $165.16 $275.42 65
10Y EBITDA Exit $113.62 $207.54 $369.84 65
10Y P/E Exit $101.27 $176.10 $295.95 62
Earnings-Based
Graham-Dodd $39.28 $245.69 $343.12 63
Lynch FV $70.76 $101.09 $131.41 61
PEG = 1.0 $70.76 $101.09 $131.41 57
EPV $65.76 $72.80 $78.68 74
Multiples
P/E Multiple $95.31 $127.08 $158.85 63
P/S Multiple $73.65 $98.20 $122.75 58
P/B Multiple $164.54 $219.39 $274.23 55
EV/EBIT $124.17 $161.04 $197.90 66
EV/EBITDA $139.75 $181.81 $223.87 67
EV/Revenue $92.51 $126.34 $160.17 54
Asset-Based
NCAV (Graham) $4.01 $6.08 $7.60 54
Growth DCF
Growth DCF $96.95 $166.53 $272.13 76
Rev-Margin DCF $96.89 $168.33 $270.45 71
Economic Profit
Residual Income $47.57 $51.89 $61.38 71
ROIC Compounder $70.81 $90.70 $109.07 72
Growth Earnings
Growth-Adj P/E $103.23 $147.47 $191.71 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 73/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 53
How much profit the company makes from its sales and capital
Quality Growth 38
Are margins and returns getting better?
Cashflow 64
Do the profits arrive as real cash?
Financial strength 92
Debt, balance sheet and risk of trouble
Investment 90
Does it invest with discipline instead of growing at any price?
Low Volatility 27
How calm the share price moves, does not count
Price momentum 38
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 52
Distance to the 52-week high, does not count
New shares 97
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleJohn MoriciEVP, CHIEF FINANCIAL OFFICER7,969 shares at $189.31$1.5MFeb 18, 2026

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 4, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Start year 2020 (pandemic). Over 10 years: +16.9% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−10.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−10.2% vs 12.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 15%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +11.2% a year for the price and +0.7% for the forecasts.
Forecast 2026 (sales)+2.8%
Forecast 2027 (sales)+3.5%
Projected 2028 (sales)+3.3%
Projected 2029 (sales)+3.1%
Projected 2030 (sales)+2.9%

Watch ALGN, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 11, 2026
AI conclusion: The integrated Invisalign and iTero digital platform forms a durable advantage in orthodontics while limited public signals leave moat durability unconfirmed.
Main risk: Rivals such as Straumann with ClearCorrect or Envista with Spark could capture share through lower-cost aligners and improved aesthetics, pressuring Align's margins and utilization in North America.
Bull case: Align could leverage its AI-enhanced digital platform and direct 3D printing advances to deepen clinician integration and expand into restorative and teen segments, offsetting competitive pressure through higher utilization and new products.
Bear case: If rivals continue gaining share and regulators mandate openness, Align's integrated workflow could lose its lock-in effect, leading to sustained margin compression and slower case growth as doctors adopt lower-cost alternatives.
Align Technology ties Invisalign case growth closely to its iTero scanners through digital workflows that now drive most submissions. This creates a durable platform advantage in orthodontics and restorative dentistry, yet recent demand signals point to possible consumer caution ahead of earnings. Will the integrated system deliver steady utilization gains or face limits from softer spending?
Join the discussion →

Compare Align Technology Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 73 · Top 25%
Fair Value upside +10.0% · Above median
Profitability
Return on equity (12 months) 10.2% · Above median
Return on assets 6.6% · Above median
Net margin (12 months) 10.0% · Above median
Operating margin (12 months) 18.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 4.3% · Below median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 24.0× · Cheaper than median
P/B 2.92× · Pricier than median
P/S (12 months) 2.85× · Pricier than median
Price / free cash flow 24.1× · Pricier than median
EV/EBITDA 11.6× · Cheaper than median
PEG 0.64× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)47 · sector 19
FUTURE (revenue growth)22 · sector 40
PAST (return on equity)41 · sector 30
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $89.35 $133.48 +49% vs ALGN
EssilorLuxottica Société anonyme EL €191.95 €196.22 +2% vs ALGN
Intuitive Surgical, Inc ISRG $482.10 $353.90 −27% vs ALGN
Medline Inc MDLN $40.35 $28.64 −29% vs ALGN
Alcon Inc ALC CHF 62.78 CHF 33.96 −46% vs ALGN
Straumann Holding STMN CHF 105.85 CHF 45.50 −57% vs ALGN
Becton, Dickinson and Company BDX $209.19 $82.34 −61% vs ALGN
West Pharmaceutical Services, Inc WST $408.78 $139.22 −66% vs ALGN
Sartorius Stedim Biotech S.A DIM €224.20 €54.82 −76% vs ALGN
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs ALGN

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Align Technology Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Align Technology Inc Fair Value". https://www.fairvalue-calculator.com/stock/ALGN

Frequently asked questions

Is Align Technology Inc (ALGN) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $181.39 versus a price of $164.90, about +10% upside (fairly valued).
What is the fair value of ALGN?
Our model-based fair value for Align Technology Inc is $181.39 (as of Nov 5, 2026), built from audited fundamentals. The current price: $164.90.
What is the quality score of ALGN?
Align Technology Inc has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Align Technology Inc (ALGN)?
Our model-based price target is the fair value of $181.39 (as of Nov 5, 2026) from 24 valuation models. Cautious scenario $119.25, optimistic scenario $235.81. It is a calculation from audited fundamentals, not an analyst target.
What is the Align Technology Inc stock forecast for 2026?
Our models put fair value at $181.39, about +10% upside versus a price of $164.90 (fairly valued). Cautious scenario $119.25, optimistic scenario $235.81. The calculation is refreshed regularly with new filings.
What is the revenue of Align Technology Inc (ALGN)?
Align Technology Inc reported trailing-twelve-month revenue of about $4.1B (latest available figure, as of Nov 5, 2026).
What growth is priced into Align Technology Inc (ALGN)?
For today's price to be fair in a discounted-cash-flow model, Align Technology Inc would have to grow free cash flow by +13.9 % per year for five years (discount rate 10.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.3 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of ALGN use?
Our models discount Align Technology Inc at 10.8 %: a base by market capitalisation (large), damped by beta 1.67, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Align Technology Inc that is +13.9 % per year a year over ten years, using the same discount rate (10.8 %) and the same formula as our fair value.
How much growth has Align Technology Inc (ALGN) delivered so far?
Over the past 5 years revenue at Align Technology Inc grew +10.3 % a year. The price currently implies +13.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Align Technology Inc (ALGN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Align Technology Inc (+13.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Align Technology Inc (ALGN)?
The free-cash-flow yield on the price is 4.16 %: that much free cash flow Align Technology Inc produces per unit of market value. When it exceeds the discount rate of our models (10.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Align Technology Inc (ALGN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Align Technology Inc it is $181.39 per share (as of Nov 5, 2026), against a price of $164.90. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Align Technology Inc stock overvalued or undervalued in 2026?
As of Nov 5, 2026, ALGN trades below its calculated fair value: price $164.90, fair value $181.39, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALGN?
No. The price is what the market pays today ($164.90); the fair value is what the company's own numbers justify ($181.39). For Align Technology Inc the two are $16.49 per share apart. That gap is exactly why we show both numbers side by side.
How much is Align Technology Inc worth?
The market values Align Technology Inc at about $11.8B (market capitalisation, as of Nov 5, 2026). Per share that is $164.90; our models calculate a fair value of $181.39 per share.
What do the bullish and bearish scenarios say about ALGN?
Our models span a range for Align Technology Inc: cautious scenario $119.25, base $181.39, optimistic $235.81 per share (as of Nov 5, 2026, price $164.90). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALGN?
Align Technology Inc trades at a price-to-earnings ratio of 24.0 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $181.39 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, 4 of the years ex one-offs: 43.7. Other multiples: PEG 0.6, P/B 2.9, P/S 2.9, EV/EBITDA 11.6.
What is the PEG ratio of ALGN?
The PEG ratio of Align Technology Inc is 0.64 (P/E divided by earnings growth, as of Nov 5, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Align Technology Inc (ALGN)?
Balance-sheet figures for Align Technology Inc (as of Nov 5, 2026): return on equity 10.2%. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is ALGN from its 52-week high?
Align Technology Inc trades at $164.90, about 17% below its 52-week high of $197.51 and 25% above the low of $132.28 (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of $181.39 is for.
Which stocks are comparable to Align Technology Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Align Technology Inc stock attractive at the current price?
The data as of Nov 5, 2026: price $164.90, calculated fair value $181.39 (+10%), Quality Score 73/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALGN calculated?
We run Align Technology Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $181.39, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. Align Technology Inc currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Align Technology Inc (ALGN)?
The closing price on Nov 4, 2026 was $164.90. Our model-based fair value is $181.39, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Align Technology Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($119.25 to $235.81) leaves room in how you read the outcome.
Where does the earnings growth of Align Technology Inc (ALGN) come from?
Earnings per share at Align Technology Inc grew +12.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +19.2 %, EBIT margin −4.4 %, tax rate −1.2 %, residual (interest, one-offs) +0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Align Technology Inc

How large is the market capitalisation of Align Technology Inc (ALGN)?
The market capitalisation of Align Technology Inc is $11.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Align Technology Inc (ALGN)?
The price-to-sales ratio of Align Technology Inc is 2.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Align Technology Inc (ALGN)?
Earnings per share at Align Technology Inc are $6.86 (price ÷ EPS = P/E 24.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Align Technology Inc (ALGN)?
The net margin of Align Technology Inc is 10.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Align Technology Inc (ALGN)?
The return on equity (ROE) of Align Technology Inc is 10.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Align Technology Inc (ALGN)?
On an EBIT basis the return on assets of Align Technology Inc is 11.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Align Technology Inc (ALGN)?
The operating margin of Align Technology Inc is 18.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Align Technology Inc (ALGN)?
Revenue at Align Technology Inc is growing +4.3% versus a year earlier (3y avg +2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Align Technology Inc (ALGN)?
Earnings per share at Align Technology Inc are growing −12.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Align Technology Inc (ALGN) hold?
Align Technology Inc holds more cash than debt, $965M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Align Technology Inc in the live analysis

One click puts Align Technology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.